August 27, 2026 | Intelligent Congress, Pharma, healthcare
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.

Congresses remain one of the most influential moments in the HCP journey, but many organizations still struggle to connect strategy, engagement, and measurement across the congress lifecycle. As a result, valuable opportunities to maximize impact are often missed.
Our latest Intelligent Congress guidebook introduces a practical four-step framework to help pharma teams transform congresses from isolated activities into connected, measurable experiences. Covering strategic alignment, integrated measurement, seamless HCP engagement, and streamlined execution, it provides a roadmap for creating more coordinated congress strategies that deliver greater business impact.
Download here.
This content was provided by Inizio
Latest Content from Inizio
Within the pharmaceutical industry, there is an increasing need for market research teams to share the insights with their key internal stakeholders, from marketing and brand managers to sales reps…
Research Partnership is delighted to announce promotions and new starters in the UK and further appointments in the US and Singapore offices
In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy…
In emerging markets where primary care systems do not exist, the patient is the only constant in the journey
Pegasus, one of the most successful integrated healthcare communications consultancies in the UK, has today announced it has been acquired by UDG Healthcare plc, a FTSE 250 listed international provider…
Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?
Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.
Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients
Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch
Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out…
